Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: Influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus

American Journal of Kidney Diseases

Volumn 41, Issue 3 SUPPL. 1, 2003, Pages

  Suliman, Mohamed E ^a   Stenvinkel, Peter ^a   Bárány, Peter ^a   Heimbürger, Olof ^a   Anderstam, Björn ^a   Lindholm, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Albumin; Cardiovascular disease (CVD); Diabetes mellitus (DM); End stage renal disease (ESRD); Homocysteine (Hcy); Inflammation; Malnutrition

Indexed keywords

ALBUMIN; HOMOCYSTEINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY FAILURE; MALNUTRITION; MORTALITY; PREDICTION; PREVALENCE;

EID: 0037373894     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50093     Document Type: Conference Paper

References (47)

1. Stenvinkel P, Heimburger O, Paultre F, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55:1899-1911, 1999
2. Qureshi AR, Alvestrand A, Danielsson A, et al: Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53:773-782, 1998
3. Canada-USA (CANUSA) Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 7:198-207, 1996
4. Qureshi AR, Alvestrand A, Divino-Filho JC, et al: Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13:S28-S36, 2002 (suppl 1)
5. Owen WF, Lew NL, Lieu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
6. Bergström J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol 6:1329-1341, 1995
7. Bergström J, Lindholm B: Malnutrition, cardiac disease and mortality: An integrated point of view. Am J Kidney Dis 32:1-10, 1998
8. Wharton BA, Howells GR, McCance RA: Cardiac failure in kwashiorkor. Lancet 2:384-387, 1967
9. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15:953-960, 2000
10. Brattström L, Wilcken DE: Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr 72:315-323, 2000
11. van Guldener C, Stam F, Stehouwer CD: Homocysteine metabolism in renal failure. Kidney Int Suppl 78:S234-S237, 2001
12. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 52: 10-20, 1997
13. Suliman ME, Stenvinkel P, Heimbürger O, et al: Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 40:480-488, 2002
14. Suliman ME, Qureshi AR, Bárány P, et al: Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int 57:1727-1735, 2000
15. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD: Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy. Perit Dial Int 18:282-289, 1998
16. Descombes E, Hanck AB, Fellay G: Water soluble vitamins in chronic hemodialysis and need for supplementation. Kidney Int 43:1319-1328, 1993
17. Jennette JC, Goldman ID: Inhibition of the membrane transport of folates by anions retained in uremia. J Lab Clin Med 86:834-843, 1975
18. Livant EJ, Tamura T, Johnston KE, et al: Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem 5:504-509, 1994
19. Shemin D, Bostom AG, Selhub J: Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis 38:S91-S94, 2001 (suppl 1)
20. Födinger M, Mannhalter C, Wölfl G, et al: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52:517-523, 1997
21. Vychytil A, Födinger M, Wölfl G, et al: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 53:1775-1782, 1998
22. Suliman ME, Lindholm B, Barany P, Bergström J: Hyperhomocysteinemia in chronic renal failure patients: Relation to nutritional status and cardiovascular disease. Clin Chem Lab Med 39:734-738, 2001
23. van Guldener C, Kulik W, Berger R, et al: Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int 56:1064-1071, 1999
24. Suliman ME, Divino-Filho JC, Barany P, Anderstam B, Lindholm B, Bergström J: Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulphhydryls before and after co-factor supplementation in haemodialysis patients. Nephrol Dial Transplant 16:102-110, 2001
25. Suliman ME, Anderstam B, Lindholm B, Bergström J: Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 12:2332-2338, 1997
26. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH: Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 79:1635-1641, 1987
27. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 29:658-668, 1997
28. Suliman ME, Stenvinkel P, Barany P, Heimburger O, Anderstam B, Lindholm B: Relationship between changes in plasma total homocysteine and serum albumin following renal replacement therapy. J Am Soc Nephrol 13:760A, 2002
29. Brulez HF, van Guldener C, Donker AJ, ter Wee PM: The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 14:154-159, 1999
30. Skoupy S, Fodinger M, Veitl M, et al: Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol 13:1331-1337, 2002
31. Suliman ME, Stenvinkel P, Barany P, Heimburger O, Anderstam B, Lindholm B: Hyperhomocysteinemia and inflammation in end-stage renal disease: Is there a link? International Congress on Mechanisms of Uremic Toxicity. Wurzburg, Germany, 2002 (abstr)
32. Oishi K, Nagake Y, Yamasaki H, et al: The significance of serum homocysteine levels in diabetic patients on haemodialysis. Nephrol Dial Transplant 15:851-855, 2000
33. Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C: Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55:1028-1035, 1999
34. Bachmann J, Tepel M, Raidt H, et al: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6:121-125, 1995
35. Chauveau P, Chadefaux B, Coude M, et al: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 41:S72-S77, 1993
36. Robinson K, Gupta A, Dennis V, et al: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748, 1996
37. Bostom AG, Shemin D, Verhoef P, et al: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vas Biol 17:2554-2558, 1997
38. Moustapha A, Naso A, Nahlawi M, et al: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97:138-141, 1998
39. Jungers P, Chauveau P, Bandin O, et al: Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 23:170-173, 1997
40. Kunz K, Petitjean P, Lisri M, et al: Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocyst(e)ine the missing link? Nephrol Dial Transplant 14:1934-1942, 1999
41. van Guldener C, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD: Carotid artery stiffness in patients with end-stage renal disease: No effect of long-term homocysteine-lowering therapy. Clin Nephrol 53:33-41, 2000
42. Refsum H, Ueland PM: Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol 9:533-539, 1998
43. Ueland PM, Refsum H, Beresford SA, Vollset SE: The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324-332, 2000
44. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277:1775-1781, 1997
45. Widner B, Enzinger C, Laich A, Wirleitner B, Fuchs D: Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metab 3:225-232, 2002
46. Vychytil A, Födinger M, Papagiannopoulos M, Wölfl G, Hörl WH, Sunder-Plassmann G: Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int 55:2054-2061, 1999
47. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:S24-S30, 1998 (suppl 12)